Overview
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Status:
Completed
Completed
Trial end date:
2014-12-01
2014-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:-Moderate to severe persistent facial erythema associated with rosacea.
Exclusion Criteria:
- Greater than 3 inflammatory lesions on the face
- Current treatment with monoamine oxidase (MAO) inhibitors
- Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or
Sjogren's syndrome.